Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical Trials Overlook Diseases of Low-Income Countries

Clinical Trials Overlook Diseases of Low-Income Countries News & Analysis Global Health High-Income Countries Have Secured Clinical Trials Overlook Diseases the Bulk of COVID-19 Vaccines of Low-Income Countries Conditions like respiratory infections, tuber- High-income countries have reserved culosis, and enteric infections that dispro- morethanhalfoftheworld’scoronavirusdis- portionatelyaffectlow-incomecountriesare ease 2019 (COVID-19) vaccine doses de- consistentlyunderstudiedinclinicaltrials,ac- spite representing just 14% of the world’s population, according to an analysis of cording to a recent study. Using machine learning technology, re- publicly available data on premarket pur- searchers in the UK and US analyzed 31 mil- chase agreements. lion articles in the PubMed database to iden- The data show that 7.48 billion doses— tify 463 000 randomized clinical trials enough to fully vaccinate about half the (RCTs) published between 1990 and mid- world’s population with 2 shots—had been 2020. Then they examined how the health secured as of mid-November 2020. But so conditionsstudiedmostofteninclinicaltrials far, high-income countries have acquired compared with conditions that cause the 51% of the doses, leaving the remainder for greatest disease burden as measured in dis- low- and middle-income countries where High-income countries that are home to only 14% ability-adjusted life-years (DALYS). 86% of the global population lives, accord- of the world’s population have secured more than Onaverage,theyfoundthatasDALYSfor ing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Clinical Trials Overlook Diseases of Low-Income Countries

Kuehn, Bridget M.
JAMA , Volume 325 (7) – Feb 16, 2021
Download PDF
1 page

Clinical Trials Overlook Diseases of Low-Income Countries

Abstract

News & Analysis Global Health High-Income Countries Have Secured Clinical Trials Overlook Diseases the Bulk of COVID-19 Vaccines of Low-Income Countries Conditions like respiratory infections, tuber- High-income countries have reserved culosis, and enteric infections that dispro- morethanhalfoftheworld’scoronavirusdis- portionatelyaffectlow-incomecountriesare ease 2019 (COVID-19) vaccine doses de- consistentlyunderstudiedinclinicaltrials,ac- spite representing just 14% of the...
Loading next page...
 
/lp/american-medical-association/clinical-trials-overlook-diseases-of-low-income-countries-SsEa8Kt2uB

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.0842
Publisher site
See Article on Publisher Site

Abstract

News & Analysis Global Health High-Income Countries Have Secured Clinical Trials Overlook Diseases the Bulk of COVID-19 Vaccines of Low-Income Countries Conditions like respiratory infections, tuber- High-income countries have reserved culosis, and enteric infections that dispro- morethanhalfoftheworld’scoronavirusdis- portionatelyaffectlow-incomecountriesare ease 2019 (COVID-19) vaccine doses de- consistentlyunderstudiedinclinicaltrials,ac- spite representing just 14% of the world’s population, according to an analysis of cording to a recent study. Using machine learning technology, re- publicly available data on premarket pur- searchers in the UK and US analyzed 31 mil- chase agreements. lion articles in the PubMed database to iden- The data show that 7.48 billion doses— tify 463 000 randomized clinical trials enough to fully vaccinate about half the (RCTs) published between 1990 and mid- world’s population with 2 shots—had been 2020. Then they examined how the health secured as of mid-November 2020. But so conditionsstudiedmostofteninclinicaltrials far, high-income countries have acquired compared with conditions that cause the 51% of the doses, leaving the remainder for greatest disease burden as measured in dis- low- and middle-income countries where High-income countries that are home to only 14% ability-adjusted life-years (DALYS). 86% of the global population lives, accord- of the world’s population have secured more than Onaverage,theyfoundthatasDALYSfor ing

Journal

JAMA – American Medical Association

Published: Feb 16, 2021

There are no references for this article.